

MNK

Mitogen activated protein kinase interacting kinase;MAP kinase interacting kinase;MAPK interacting kinase

HDAC Inhibitor:
Vorinostat (SAHA)



HDAC (Histone deacetylase)

Mitogen-activated protein kinase-interacting kinases 1 and 2 (MNK1 and MNK2) phosphorylate the oncogene eIF4E on serine 209. This phosphorylation has been reported to be required for its oncogenic activity. Eukaryotic initiation factor 4E (eIF4E) is a key component of the translational machinery and an important modulator of cell growth and proliferation. The activity of eIF4E is thought to be regulated by interaction with inhibitory binding proteins (4E-BPs) and phosphorylation by mitogen-activated protein (MAP) kinase-interacting kinase (MNK) on Ser209 in response to mitogens and cellular stress.

MNK Inhibitors & Modulators

Cercosporamide

(-)-Cercosporamide)


Cat. No.: HY-16982

Bioactivity: Cercosporamide is a highly potent, ATP-competitive **Pkc1** kinase inhibitor, with an **IC₅₀** of <50 nM and a **K_i** of <7 nM. Cercosporamide is a unique **Mnk** inhibitor.

Purity: >98%

Clinical Data: No Development Reported

Size: 500u g, 1 mg



CGP 57380


Cat. No.: HY-10520

Bioactivity: CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of **Mnk1** with **IC₅₀** of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.

Purity: 98.48%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



ETC-206


Cat. No.: HY-112424

Bioactivity: ETC-206 is a selective **MNK1** and **MNK2** inhibitor with **IC₅₀s** of 64 nM and 86 nM, respectively.

Purity: 99.76%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



SLV-2436

(SEL201-88; SEL-201)


Cat. No.: HY-112113

Bioactivity: SLV-2436 is a highly potent and ATP-competitive inhibitor of **MNK1** and **MNK2** with **IC₅₀s** of 10.8 nM and 5.4 nM, respectively.

Purity: 98.13%

Clinical Data: No Development Reported

Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Tomivosertib

(eFT508)

Cat. No.: HY-100022

Bioactivity: Tomivosertib (eFT508) is a potent, highly selective, and orally bioavailable **MNK1** and **MNK2** inhibitor, with **IC₅₀s** of 1-2 nM against both isoforms.

Purity: 99.49%

Clinical Data: Phase 2

Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 50 mg, 100 mg

